关于丙型肝炎直接抗病毒药物疗法的Cochrane系统评价结论是错误的。 - Suppr

The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong.

作者信息

Kwo Paul Y, Shiffman Mitchell L, Bernstein David E

机构信息

Division of Gastroenterology/Hepatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California, USA.

Bon Secours Liver Institute of Virginia, Bon Secours Medical Group, Newport News and Richmond, Virginia, USA.

出版信息

Am J Gastroenterol. 2018 Jan;113(1):2-4. doi: 10.1038/ajg.2017.420. Epub 2017 Nov 14.

DOI:10.1038/ajg.2017.420

PMID:29134963

Abstract

摘要

相似文献

The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong.关于丙型肝炎直接抗病毒药物疗法的Cochrane系统评价结论是错误的。

Am J Gastroenterol. 2018 Jan;113(1):2-4. doi: 10.1038/ajg.2017.420. Epub 2017 Nov 14.

Reply to: "Extended DAA indications for hepatitis C patients awaiting liver transplantation and further statistical considerations".

J Hepatol. 2018 Mar;68(3):627-628. doi: 10.1016/j.jhep.2017.10.009. Epub 2017 Nov 14.

[Current management of hepatitis C].[丙型肝炎的当前管理]

Med Monatsschr Pharm. 2015 Sep;38(9):337-44; quiz 345-6.

[Hepatitis C: Innovations in the last 10 years].[丙型肝炎：过去十年的创新]

MMW Fortschr Med. 2018 Nov;160(Suppl 3):66-70. doi: 10.1007/s15006-018-1127-3.

How effective and how durable is DAA-therapy in HCV-infected drug users?直接抗病毒药物疗法对丙型肝炎病毒感染的吸毒者有多大效果以及疗效能持续多久？

Liver Int. 2019 Dec;39(12):2238-2239. doi: 10.1111/liv.14284.

In DAA We Trust: Key Factors Essential to HCV Elimination.我们信赖直接抗病毒药物：丙型肝炎病毒消除的关键要素

Dig Dis Sci. 2019 Oct;64(10):2701-2702. doi: 10.1007/s10620-019-05748-7.

[Recent advances in the treatment of hepatitis C in 2016].

Zhonghua Gan Zang Bing Za Zhi. 2017 Mar 20;25(3):175-180. doi: 10.3760/cma.j.issn.1007-3418.2017.03.004.

DAA failures in African patients with "unusual" HCV subtypes: Hey! Didn't you know there was another world?非洲“不常见”丙型肝炎病毒（HCV）亚型患者中直接抗病毒药物（DAA）治疗失败：嘿！你难道不知道还有另一个世界吗？

J Hepatol. 2019 Dec;71(6):1070-1072. doi: 10.1016/j.jhep.2019.09.021. Epub 2019 Oct 21.

Prevention and management of treatment failure to new oral hepatitis C drugs.新型口服抗丙肝药物治疗失败的预防和管理。

Expert Opin Pharmacother. 2016 Jun;17(9):1215-23. doi: 10.1080/14656566.2016.1182156. Epub 2016 May 9.

New hepatitis C therapies for special patient populations.针对特殊患者群体的新型丙型肝炎治疗方法。

Expert Opin Pharmacother. 2016;17(2):217-29. doi: 10.1517/14656566.2016.1112790. Epub 2015 Nov 23.

引用本文的文献

Identifying experts for clinical practice guidelines: perspectives from the ASH Guideline Oversight Subcommittee.确定临床实践指南的专家：来自美国血液学会指南监督小组委员会的观点

Blood Adv. 2023 Aug 22;7(16):4323-4326. doi: 10.1182/bloodadvances.2023010039.

Hepatitis C virus: A critical approach to who really needs treatment.丙型肝炎病毒：关于真正需要治疗人群的关键探讨。

World J Hepatol. 2022 Jan 27;14(1):1-44. doi: 10.4254/wjh.v14.i1.1.

Risk of Hepatocellular Carcinoma Following Use of Direct Acting Antiviral Medications for Treatment of Chronic Hepatitis C.直接作用抗病毒药物治疗慢性丙型肝炎后肝细胞癌的风险。

Cancer Prev Res (Phila). 2019 Dec;12(12):891-902. doi: 10.1158/1940-6207.CAPR-19-0162. Epub 2019 Aug 26.

The interleukin 28B gene polymorphism, rs8099917, in patients with chronic hepatitis C and response to the treatment with pegylated interferon and ribavirin.慢性丙型肝炎患者白细胞介素28B基因多态性rs8099917与聚乙二醇干扰素和利巴韦林治疗反应的关系

J Res Med Sci. 2019 Feb 25;24:12. doi: 10.4103/jrms.JRMS_621_18. eCollection 2019.

本文引用的文献

Direct-acting antivirals for chronic hepatitis C.用于慢性丙型肝炎的直接作用抗病毒药物。

Cochrane Database Syst Rev. 2017 Jun 6;6(6):CD012143. doi: 10.1002/14651858.CD012143.pub2.

Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.格卡瑞韦和哌仑他韦在无肝硬化的 HCV 基因 1-6 型患者中产生高应答率。

J Hepatol. 2017 Aug;67(2):263-271. doi: 10.1016/j.jhep.2017.03.039. Epub 2017 Apr 13.

The impact of antiviral therapy for hepatitis C on the quality of life: a perspective.抗病毒治疗丙型肝炎对生活质量的影响：一个观点。

Liver Int. 2017 Jan;37 Suppl 1:7-12. doi: 10.1111/liv.13292.

Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy.直接抗病毒治疗时代肝移植等待名单的减少

Hepatology. 2017 Mar;65(3):804-812. doi: 10.1002/hep.28923. Epub 2016 Dec 24.

Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study.慢性丙型肝炎病毒清除后肝移植候选人的除名：一项欧洲研究。

J Hepatol. 2016 Sep;65(3):524-31. doi: 10.1016/j.jhep.2016.05.010. Epub 2016 May 17.

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.雷迪帕韦和索非布韦联合利巴韦林治疗基因型 1 或 4 型丙型肝炎病毒感染和晚期肝病患者：一项多中心、开放标签、随机、2 期临床试验。

Lancet Infect Dis. 2016 Jun;16(6):685-697. doi: 10.1016/S1473-3099(16)00052-9. Epub 2016 Feb 18.

Colonoscopy Reduces Colorectal Cancer Incidence and Mortality in Patients With Non-Malignant Findings: A Meta-Analysis.结肠镜检查可降低非恶性病变患者的结直肠癌发病率和死亡率：一项荟萃分析。

Am J Gastroenterol. 2016 Mar;111(3):355-65. doi: 10.1038/ajg.2015.418. Epub 2016 Jan 12.

A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver • April 22-26, 2015 • Vienna, AustriaSpecial Reporting on:• Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients With Advanced Cirrhosis or Posttransplant Recurrence: Phase 3 ALLY-1 Study• Efficacy and Safety of Grazoprevir and Elbasvir in Hepatitis C Genotype 1-Infected Patients With Child-Pugh Class B Cirrhosis (C-SALT Part A)• Ledipasvir/Sofosbuvir With Ribavirin Is Safe and Efficacious in Decompensated and Post Liver Transplantation Patients With HCV Infection: Preliminary Results of the Prospective SOLAR 2 Trial• Retreatment of Patients Who Failed 8 or 12 Weeks of Ledipasvir/Sofosbuvir-Based Regimens With Ledipasvir/Sofosbuvir for 24 Weeks• Sofosbuvir + Peginterferon/Ribavirin for 12 Weeks Vs Sofosbuvir + Ribavirin for 16 or 24 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients With Genotype 2 HCV: The BOSON Study• Safety and Efficacy of the Combination Daclatasvir-Sofosbuvir in HCV Genotype 1-Mono-Infected Patients From the French Observational Cohort ANRS CO22 HEPATHER• C-SWIFT: Grazoprevir/Elbasvir + Sofosbuvir in Cirrhotic and Noncirrhotic, Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection for Durations of 4, 6 or 8 Weeks and Genotype 3 Infection for Durations of 8 or 12 WeeksPLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MD Chief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois.特别会议回顾版：2015年欧洲肝脏研究学会（EASL）第50届年会丙肝病毒感染治疗进展•2015年4月22 - 26日•奥地利维也纳特别报道：• 达卡他韦、索磷布韦和利巴韦林联合治疗晚期肝硬化或移植后复发丙肝患者：3期ALLY - 1研究• 格卡瑞韦和艾尔巴韦治疗Child - Pugh B级肝硬化的丙肝基因1型感染患者的疗效和安全性（C - SALT A部分）• 来迪派韦/索磷布韦联合利巴韦林治疗失代偿期及肝移植后丙肝感染患者安全有效：前瞻性SOLAR 2试验初步结果• 基于来迪派韦/索磷布韦方案治疗8周或12周失败的患者采用来迪派韦/索磷布韦再治疗24周• 索磷布韦 + 聚乙二醇干扰素/利巴韦林治疗12周与索磷布韦 + 利巴韦林治疗16周或24周用于基因3型丙肝感染患者及有治疗经验的基因2型丙肝肝硬化患者：BOSON研究• 达卡他韦 - 索磷布韦联合治疗法国观察性队列ANRS CO22 HEPATHER中丙肝基因1型单感染患者的安全性和有效性• C - SWIFT：格卡瑞韦/艾尔巴韦 + 索磷布韦治疗初治的基因1型丙肝病毒感染的肝硬化和非肝硬化患者4、6或8周，以及基因3型感染患者8或12周加会议摘要及专家评论作者：医学博士史蒂文·L·弗拉姆西北大学费恩伯格医学院肝脏移植项目主任医学与外科学教授伊利诺伊州芝加哥市

Gastroenterol Hepatol (N Y). 2015 Jun;11(6 Suppl 3):1-23.

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.simeprevir联合索磷布韦（无论是否联用利巴韦林）用于HCV 1型感染的真实世界患者的有效性

Gastroenterology. 2016 Feb;150(2):419-29. doi: 10.1053/j.gastro.2015.10.013. Epub 2015 Oct 21.

Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.使用直接作用抗病毒药物治疗丙型肝炎病毒相关混合性冷球蛋白血症。

Hepatology. 2016 Feb;63(2):408-17. doi: 10.1002/hep.28297. Epub 2015 Dec 11.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献